- Conditions
- Atopic Dermatitis
- Interventions
- Tralokinumab + TCS, Placebo + TCS
- Drug
- Lead sponsor
- LEO Pharma
- Industry
- Eligibility
- 6 Months to 11 Years
- Enrollment
- 195 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • North Little Rock, Arkansas • Palo Alto, California + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Gastroesophageal Reflux
- Interventions
- pantoprazole for approximately 9 weeks.
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 1 Year to 11 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 23
- States / cities
- Little Rock, Arkansas • Orange, California • San Diego, California + 19 more
- Conditions
- Autism, Autistic Disorder, Asperger's Disorder, PDD, Pervasive Developmental Disorder
- Interventions
- Gammaplex 5%
- Drug
- Lead sponsor
- Isaac Melamed
- Industry
- Eligibility
- 4 Years to 12 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Centennial, Colorado
- Conditions
- High Risk Acute Lymphoblastic Leukemia
- Interventions
- Hybrid Closed Loop System
- Device
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 10 Years to 26 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Sickle Cell Disease
- Interventions
- PCV21, 20vPCV
- Biological
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Omaha, Nebraska • New Brunswick, New Jersey + 1 more
- Conditions
- Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Ganglioglioma, Anaplastic Meningioma, Anaplastic Oligodendroglioma, Pleomorphic Xanthoastrocytoma, Anaplastic, Atypical Teratoid/Rhabdoid Tumor, Brain Cancer, Brain Tumor, Central Nervous System Neoplasms, Choroid Plexus Carcinoma, CNS Embryonal Tumor With Rhabdoid Features, Ganglioneuroblastoma of Central Nervous System, CNS Tumor, Embryonal Tumor of CNS, Ependymoma, Glioblastoma, Glioma, Glioma, Malignant, Medulloblastoma, Medulloblastoma; Unspecified Site, Medulloepithelioma, Neuroepithelial Tumor, Neoplasms, Neoplasms, Neuroepithelial, Papillary Tumor of the Pineal Region (High-grade Only), Pediatric Brain Tumor, Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only), Pineoblastoma, Primitive Neuroectodermal Tumor, Recurrent Medulloblastoma, Refractory Brain Tumor, Neuroblastoma. CNS, Glioblastoma, IDH-mutant, Glioblastoma, IDH-wildtype, Medulloblastoma, Group 3, Medulloblastoma, Group 4, Glioma, High Grade, Neuroepithelial Tumor, High Grade, Medulloblastoma, SHH-activated and TP53 Mutant, Medulloblastoma, SHH-activated and TP53 Wildtype, Medulloblastoma, Chromosome 9q Loss, Medulloblastoma, Non-WNT Non-SHH, NOS, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, PTCH1 Mutation, Medulloblastoma, WNT-activated, Ependymoma, Recurrent, Glioma, Recurrent High Grade, Glioma, Recurrent Malignant, Embryonal Tumor, NOS, Glioma, Diffuse Midline, H3K27M-mutant, Embryonal Tumor With Multilayered Rosettes (ETMR), Ependymoma, NOS, WHO Grade III, Ependymoma, NOS, WHO Grade II, Medulloblastoma, G3/G4, Ependymoma, RELA Fusion Positive
- Interventions
- Gemcitabine, ribociclib, sonidegib, trametinib, filgrastim
- Drug · Biological
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 1 Year to 39 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Pneumococcal Conjugate Vaccine
- Interventions
- 13-valent Pneumoccocal Conjugate Vaccine
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Louisville, Kentucky • The Bronx, New York + 1 more
- Conditions
- Heart Arrest, Out-Of-Hospital, Wounds and Injuries, Respiratory Insufficiency in Children, Child, Only, Critical Illness
- Interventions
- BVM, SGA, ETI
- Device
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 24 Hours to 17 Years
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 10
- States / cities
- Tucson, Arizona • Los Angeles, California • Sacramento, California + 7 more
- Conditions
- Type 2 Diabetes
- Interventions
- Bromocriptine mesylate
- Drug
- Lead sponsor
- VeroScience
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • New Haven, Connecticut • Miami, Florida + 2 more
- Conditions
- FSGS
- Interventions
- APL2, Placebo
- Drug · Other
- Lead sponsor
- Apellis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • New York, New York
- Conditions
- Autism Spectrum Disorder
- Interventions
- Linguistic simplification
- Behavioral
- Lead sponsor
- Michigan State University
- Other
- Eligibility
- 1 Year to 4 Years
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- East Lansing, Michigan
- Conditions
- Acute Pyelonephritis, Complicated Urinary Tract Infection
- Interventions
- Meropenem-Vaborbactam, Antibiotics
- Drug
- Lead sponsor
- Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)
- Industry
- Eligibility
- 3 Months to 11 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 4
- States / cities
- Little Rock, Arkansas • Orange, California • Omaha, Nebraska + 1 more
- Conditions
- RSV Infection
- Interventions
- Nirsevimab
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 0 Years to 2 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Tampa, Florida • Syracuse, New York + 4 more
- Conditions
- Child, Only, Brain Diseases, Sickle Cell Disease, Anemia, Sickle Cell
- Interventions
- Carbon Dioxide
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 4 Years to 21 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- MRI Sedation, Pediatric Sedation, Propofol Dosage, Emergence Delirium, Anesthesia, Recovery Time, Dexmedetomidine
- Interventions
- Dexmedetomidine (IV) 0.5 mcg/kg, Propofol (IV) 2-4 mg/kg, Dexmedetomidine (IV) 1 mcg/kg, Propofol (IV) 1-2 mg/kg, Propofol (IV) Infusion 250 mcg/kg/min, Propofol (IV) Infusion 150 mcg/kg/min
- Drug
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 1 Year to 12 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- HIV Infections
- Interventions
- Abacavir sulfate, Lamivudine, Stavudine, Zidovudine, Didanosine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 3 Months to 13 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1998
- U.S. locations
- 7
- States / cities
- Los Angeles, California • San Diego, California • New Orleans, Louisiana + 4 more
- Conditions
- Hepatic; Functional Disturbance
- Interventions
- NKTR-118
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- Guanfacine, Methylphenidate (MPH)
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 7 Years to 14 Years
- Enrollment
- 212 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Autism Spectrum Disorder
- Interventions
- Balovaptan, Esomeprazole
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Diabetes Mellitus, Type 1 Diabetes, Diabetes Mellitus, Type 1
- Interventions
- Bionic Pancreas (BP) with Aspart or Lispro, Bionic Pancreas with Fiasp (BPFiasp), Usual Care (UC), BP Guidance Insulin Dosing
- Combination Product · Other
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 6 Years and older
- Enrollment
- 440 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 16
- States / cities
- Orange, California • San Diego, California • Stanford, California + 13 more
- Conditions
- Healthy Female Participants
- Interventions
- Zibotentan, EE/LNG
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 35 Years to 75 Years · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Brooklyn, Maryland
- Conditions
- Asthma in Children
- Interventions
- Clinical decision support + education (CDS+), Control
- Behavioral · Other
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 5 Years to 18 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- filgrastim, amifostine trihydrate, cisplatin, cyclophosphamide, vincristine sulfate, peripheral blood stem cell transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 3 Years to 20 Years
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2007
- U.S. locations
- 2
- States / cities
- Memphis, Tennessee • Houston, Texas
- Conditions
- Hepatocellular Carcinoma, Cirrhosis, Liver
- Interventions
- Tremelimumab, Durvalumab
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- San Antonio, Texas